Pharmaceuticals

Biosimilars Market Expected to Reach $48.52 Billion by 2030 at 17.4% CAGR

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Biosimilars Market During 2026–2030?

The biosimilars market has seen rapid growth in its size in recent years. It is projected to increase from $21.85 billion in 2025 to $25.53 billion in 2026, at a compound annual growth rate (CAGR) of 16.9%. This past growth can be attributed to factors such as the rising prevalence of chronic and autoimmune diseases, the high cost of originator biologics, an increasing demand for cost-effective therapies, advancements in biopharmaceutical R&D, and the growing healthcare infrastructure in emerging economies.

The biosimilars market is projected to experience substantial expansion in the coming years. This market is forecast to reach $48.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.4%. Key drivers for this growth during the forecast period include the expiry of patents for major biologics, a rise in the use of biosimilars within oncology and autoimmune therapy, favorable government incentives and supportive policies, the broadening of manufacturing capabilities across Asia-Pacific, and an increase in collaborations between biopharmaceutical firms and contract manufacturing organizations. Significant trends anticipated in this period encompass the development of personalized biosimilars, the production of biologics in a cost-effective manner, the alignment and adherence to regulatory standards, the penetration of biosimilars into emerging markets, and strategic alliances and partnerships.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Underlying Factors Are Accelerating The Growth Of The Biosimilars Market?

Rising healthcare costs are anticipated to fuel the expansion of the biosimilars market in the future. These expenditures encompass all financial outlay for medical products and services within a specific population or healthcare framework. The biosimilars market contributes to the reduction of healthcare expenditures by providing economical alternatives to costly biologic medications, thus decreasing the financial burden of treatment for both patients and healthcare systems. As an illustration, in March 2024, data from the Health Foundation, an independent UK charity and think tank, indicated that for the most recent confirmed spending year, 2022/23, overall health expenditures in England amounted to £182 billion ($196.78 billion). Although projected health spending is expected to climb to £192 billion ($207.59 billion) by 2024/25, inflationary pressures mean that the actual increase in real terms will be a mere 0.6% when contrasted with the 2023/24 fiscal year. Consequently, the escalation of healthcare expenditures is stimulating the growth of the biosimilars market.

How Are The Various Segments Of The Biosimilars Market Categorized?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

What Trends Are Affecting The Expansion Of The Biosimilars Market?

Major companies in the biosimilars market focus on developing innovative products to gain a competitive edge. FYLNETRA is a leukocyte growth factor prescribed to decrease the incidence of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. For instance, in May 2023, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, commercially launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar referencing Neulasta, presented in a pre-filled single-dose syringe. FYLNETRA is utilized to treat neutropenia (low neutrophils, which are a type of white blood cells crucial for fighting infection), a condition commonly experienced by patients undergoing chemotherapy.

Which Major Firms Influence Developments In The Biosimilars Market?

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Read the full biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Region Is Projected To Dominate The Biosimilars Market During The Forecast Period?

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795